THE: FIGARO: – What is this promising new Alzheimer’s drug?
Professor Frederic BLANC. – It is a molecule called lecanemab. It is a monoclonal antibody, meaning a drug that stimulates the patient’s immune system to destroy certain biological markers of the disease, namely amyloid plaques, these protein aggregates that are found in the brains of Alzheimer’s patients. After a clinical trial that lasted eighteen months and whose results were published at a congress in December 2022, several positive results were noted.
First, a reduction in these amyloid plaques, as well as another protein, phospho-tau, which is a hallmark of a common disorder in patients called neurofibrillary degeneration. Second, lecanemab had a small, but very real, positive effect on patients’ cognition as measured by clinical scales. And above all, the patients worked…
Source: Le Figaro
I am John Sinkler, a professional writer and journalist for Buna Times. I specialize in writing about entertainment-related topics and have been doing so for several years now. My work has been featured on multiple platforms and I’m proud to say that it’s gained recognition from many people in the industry. Aside from working at Buna Times, I also write freelance articles for other publications.